NewAmsterdam Pharma Company NV（NAMS）の財務NAMSNewAmsterdam Pharma Company NV

Evaluating the bottom line, NewAmsterdam Pharma Company N.V. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1752.61%, while the net margin is -1732.91%. These profitability ratios, combined with a Return on Equity (ROE) of -36.81%, provide a clear picture of how effectively NAMS converts its operational activities into shareholder value.

In the context of the broader market, NAMS competes directly with industry leaders such as TARS and ARQT. With a market capitalization of $3.23B, it holds a significant position in the sector. When comparing efficiency, NAMS's gross margin of 100.00% stands against TARS's 93.03% and ARQT's 91.58%. Such benchmarking helps identify whether NewAmsterdam Pharma Company N.V. is trading at a premium or discount relative to its financial performance.

NewAmsterdam Pharma has faced significant financial challenges, with a net loss of $64.1 million reported in Q2 2026, up from a $17.4 million loss in Q2 2025. The revenue for Q2 2026 was only $3.7 million, an 80.7% decline year-over-year, indicating severe operational difficulties.